期刊文献+

腹膜透析患者血清铁调素25、肿瘤坏死因子α水平和颈动脉粥样硬化的关系 被引量:6

The Relationship Between the Level of Serum Hepcidin-25 and Tumor Necrosis Factor-α and Carotid Atherosclerosis in Peritoneal Dialysis Patients
下载PDF
导出
摘要 目的探讨持续性腹膜透析患者血清铁调素25、肿瘤坏死因子α水平和颈动脉粥样硬化程度的关系。方法通过酶联免疫法测定178例维持性腹膜透析患者血清铁调素25水平,采用高分辨二维超声诊断仪对双侧颈总动脉内膜中膜厚度及颈动脉粥样斑块进行测量。结果颈动脉硬化组患者血清铁调素25水平高于无颈动脉硬化组和健康对照组,两组间比较差异均有统计学意义(均P<0.01)。直线相关分析提示血清铁调素25水平与颈动脉内膜中膜厚度呈正相关关系(r=0.685,P=0.001);而且多元逐步回归分析结果发现,血清铁调素25和肿瘤坏死因子α水平是影响颈动脉内膜中膜厚度的独立危险因素。结论血清铁调素25、肿瘤坏死因子α水平均是影响维持性腹膜透析患者颈动脉粥样硬化程度的独立危险因素,可作为动脉粥样硬化预测的危险因子。 Aim To evaluate the relationship between the level of serum hepcidin-25 and tumor necrosis factor-α (TNF-α) and carotid artery atherosclerosis in peritoneal dialysis patients. Methods The serum level of hepcidin-25 of 178 maintenance peritoneal dialysis patients was determined by enzyme-linked immunoassay. The bilateral common carotid artery intima-media thickness (IMT) and carotid artery atheromatous plaque was measured by high resolution two-dimensional ultrasonic diagnostic apparatus. Results The serum hepcidin-25 level of the patients with carotid atherosclerosis group was higher than that without carotid atherosclerosis group and healthy controls group. The difference between the two groups was statistically significant (both P〈0.01). Linear correlation analysis of serum hepcidin-25 levels and carotid IMT was positive(r=0.685, P=0.001). Multiple stepwise regression analysis showed that serum hepcidin-25 and TNF-α levels were independent risk factors for carotid IMT. Conclusions The level of serum hepcidin-25 and tumor necrosis factor-α are independent risk factors of the carotid atherosclerosis in the maintenance peritoneal dialysis patients. It suggested that the level of serum hepcidin-25 and tumor necrosis factor-α can be used as a prediction of atherosclerosis risk factors.
出处 《中国动脉硬化杂志》 CAS CSCD 北大核心 2013年第12期1093-1096,共4页 Chinese Journal of Arteriosclerosis
基金 广西自然科学基金资助项目(2012JJAA40611)
关键词 腹膜透析 铁调素25 肿瘤坏死因子Α 颈动脉粥样硬化 Peritoneal Dialysis Hepcidin-25 Tumor Necrosis Factor-α Carotid Athemsclerosis
  • 相关文献

参考文献15

  • 1Lee YK,Lee DH,Kim JK. Lysophosphatidylcholine,oxidized low-density lipoprotein and cardiovascular disease in Korean hemodialysis patients:analysis at 5 years of follow-up[J].{H}Journal of Korean Medical Science,2013,(2):268-273.
  • 2Shah SV,Alam MG. Role of iron in atherosclerosis[J].{H}American Journal of Kidney Disease,2003,(Suppl 1):S80-S83.
  • 3Kuragano T,Itoh K,Shimonaka Y. Hepcidin as well as TNFα are significant predictors of arterial stiffness in patients on maintenance hemodialysis[J].{H}Nephrology Dialysis Transplantation,2011,(8):2663-2667.
  • 4Kuragano T,Shimonaka Y,Kida A. Determinants of hepcidin in patients on maintenance hemodialysis:role of inflammation[J].{H}AMERICAN JOURNAL OF NEPHROLOGY,2010,(6):534-540.
  • 5Peters HP,Laarakkers CM,Swinkels DW. Serum hepcidin25 levels in patients with chronic kidney disease are independent of glomerular filtration rate[J].{H}Nephrology Dialysis Transplantation,2010,(3):848-853.
  • 6Zaritsky J,Young B,Wang HJ. Hepcidin:a potential novel biomarker for iron status in chronic kidney disease[J].Clin J Am Soc Nephrol,2009,(6):1051-1056.
  • 7van der Weerd NC,Grooteman MP,Bots ML. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents[J].PLoS One,2012,(7):e39783.
  • 8Costa E,Swinkels DW,Laarakkers CM. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients[J].{H}ACTA HAEMATOLOGICA,2009,(4):226-229.
  • 9Zaritsky J,Young B,Gales B. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients[J].Clin J Am Soc Nephrol,2010,(6):1010-1014.
  • 10Kiechl S,Aichner F,Gerstenbrand F. Body iron stores and presence of carotid atherosclerosis:Results from the Bruneck Study[J].{H}Arteriosclerosis Thrombosis,1994,(10):1625-1630.

二级参考文献22

  • 1Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the Ameri- can heart association[J]. Circulation, 2012, 125 (1) : e2-e220.
  • 2Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a muhimarker strategy [J]. Circulation, 2003, 108 (3): 250-252.
  • 3Kleiman NS, Lakkis N, Cannon CP, et al. Prospective a- nalysis of creatine kinase muscle-brain fraction and compar- ison with troponin T to predict cardiac risk and benefit of an invasive strategy in pahents coronary syndromes [ J ]. J (6) : 1 044-050.
  • 4Dorn GW. Periostin and myocardial repair, regeneration, and recovery[J]. N Engl J Med, 2007, 357 (15) : 1 552- 554.
  • 5Wang F, Song Y, Jiang Y, et al. Associations among Peri- ostin gene polymorphisms, clinical parameters and heart failure: a case-control study in 1104 Chinese individuals [J]. J Cardiovasc Med, 2011, 12 (7) : 469-474.
  • 6Li G, Oparil S, Sanders JM, et al. Phosphatidylinositol-3- kinase signaling mediates vascular smooth muscle cell ex- pression of Periostin in vivo and in vitro [ J ]. Atherosclero- sis, 2006, 188 (2) : 292-300.
  • 7Bagnato C, Thumar J, Mayya V, et al. Proteomies analysis of human coronary atherosclerotie plaque : a feasibility stud- y of direct tissue proteomics by liquid chromatography and tandem mass spectrometry [ J ]. Mol Cell Proteomies, 2007, 6 (6) : 1 088-102.
  • 8Oka T, Xu J, Kaiser RA, et al. Genetic manipulation of Periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling[J]. Circ Res, 2007, 101 (3) : 313-321.
  • 9Kuhn B, del Monte F, Hajjar RJ, et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair[J]. Nat Med, 2007, 13 (8) : 962-969.
  • 10Koenig W, Sund M, Frohlich M, et al. C-Reactive pro- tein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle- aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease ) Augsburg Cohort Study, 1984 to 1992 [ J]. Circulation, 1999, 99 (2) : 237-242.

共引文献52

同被引文献53

  • 1涂曦文,彭佑铭,唐东兴,谭太发,李丽文.维持性血液透析患者血管钙化及相关因素分析[J].中国动脉硬化杂志,2015,23(6):613-616. 被引量:24
  • 2Zaritsky J,Young B1Wang HJ,et al.Hepcidin-a potential novel biomarker for iron status in chronic kidney disease[J].Clin J Am Soc Nephrol,2009,4:1051-1056.
  • 3美国NKF-K/DOQI工作组.慢性肾脏病及透析的临床实践指南(附评述}[M].王海燕,王梅,左力,等,译.北京:人民卫生出版社,2003:13-15.
  • 4Malyszko J,Malyszko JS,Kozminski P,et al.Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin[J].Ren Fail,2009,31(10):876-883.
  • 5刘章锁,王沛.K/DOQI指南关于慢性肾脏病分期的临床指导意义[J].中国实用内科杂志,2008,28(1):21-24. 被引量:114
  • 6Krediet RT,Struijk DG. Peritoneal changes in patients onlong-term peritoneal dialysis[J]. Nat Rev Nephrol,2013,9(7):419-429.
  • 7Diao JN,Sheng MX,Zhu XX,et al. The influence of RadixAstragali injection on dialysis efficiency and peritonealstructure of rat with high permeability of the peritonealdialysis[J], J Nanjing Univ Tradit Chin Med* 2011, 27(1):58-62.
  • 8Chinashi H,Ito Y, Mizuno M, et al. TGF-叫 promoteslymphangiogenesis during peritoneal fibrosis [J]. J AmSoc Nephrol,2013,24(10) : 1627-1642.
  • 9姜燕,龚燕梅,曾红兵,刘晓城.苦参碱对实验性大鼠腹膜纤维化的影响[J].中国医院药学杂志,2008,28(24):2110-2112. 被引量:7
  • 10李军,司维柯,赵宸,李招权,潘静.苦参碱与氧化苦参碱影响荷瘤小鼠肿瘤生长及其免疫调节作用的研究[J].重庆医学,2011,40(27):2719-2721. 被引量:20

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部